The actual guarantee balance provided by Anhui Conch Cement (00914) to Xi Ba Company is 122.44 million US dollars.
Anhui Conch Cement (00914) announced that its joint venture company, Xiba Company, has applied for a credit line of $40 million (approximately RMB 287.15 million) from CITIC BANK (International), with a term of 1 year. The controlling shareholder of the company and Xiba Company (PT Conch South Pacific Limited, a subsidiary of Conch Cement) and another shareholder of Xiba Company, Guangdong Rising Mineral Investment Co., Ltd. (a subsidiary of China Resources Mining) have signed a guarantee and compensation agreement with CITIC BANK (International). The company will provide an unconditional and irrevocable guarantee for the above credit in proportion to its 49% shareholding, corresponding to a guarantee amount of $19.6 million (approximately RMB 140.7 million). China Resources Mining will provide an unconditional and irrevocable guarantee for the above credit in proportion to its 51% equity, corresponding to a guarantee amount of $20.4 million (approximately RMB 146.45 million).
As of the date of this announcement, apart from the guarantees provided in this transaction, the company has provided guarantees for Xiba Company with an outstanding balance of $122.44 million (approximately RMB 878.98 million).
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025